Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial

Documenti analoghi

• Cytokines and chemokines in patients with chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: A systematic review
  di: Claudia Cutellè, et al.
  Pubblicazione: (2024)
• Do corticosteroids aggravate pure motor chronic inflammatory demyelinating polyneuropathy?
  di: Norito Kokubun, et al.
  Pubblicazione: (2024)
• Variability in Conduction Block Definitions Affects the Sensitivity of Diagnostic Criteria for Multifocal Motor Neuropathy
  di: Lucas Immich Gonçalves, et al.
  Pubblicazione: (2025)
• Longitudinal Assessment of Quality of Life and Functionality by CAP ‐ PRI in Patients With Active Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  di: Ivo Bozovic, et al.
  Pubblicazione: (2025)
• Eculizumab as a Disease‐Modifying Therapy in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Case Report
  di: Edoardo Dalmato Schilke, et al.
  Pubblicazione: (2025)